INTRODUCTIONDrug Discovery Strategies for Neglected Tropical DiseasesPART I: VIRUSESTowards Antiviral Therapies for the Treatment of Zika Virus InfectionDeveloping Therapeutics for Ebola Virus DiseasePART II: KINETOPLASTSDesigning drugs to target Trypanosoma cruzi, the etiological agent of Chagas diseaseDrug Discovery and Development for human African trypanosomiasisDrug Discovery and development for LeishmaniasisPART III. HELMINTHIC PARASITESOnchocerciasis Drug DiscoveryDrug Discovery and Development for Schistosomiasis Soil transmitted helminthiasis - challenges with discovery of novel anthelmintics Drug discovery and development for the treatment of EchinococcosisNew insights in the treatment of foodborne trematode InfectionsPART IV: BACTERIABuruli ulcerDrug Discovery and Development for Leprosy
David Swinney, PhD, is the chief executive officer of the Institute for Rare and Neglected Diseases Drug Discovery (iRND3). Dr. Swinney has devoted the majority of his career to analyzing and implementing drug discovery strategies that will increase the chance of success.Michael Pollastri holds the chair of chemistry and chemical biology at Northeastern University in Boston. He came to NEU from Pfizer, where he worked for 10 years as a research chemist. His research focus is discovery of new therapeutics for neglected tropical diseases.